Identification of by-products in support of process development of Muraglitazar
| Autor: | Shankar Swaminathan, Russell Suda, Venkatapuram A. Palaniswamy, Andrew Rusowicz, Charles Pathirana |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Reaction conditions
Chromatography Process development Chemistry General Chemistry 030226 pharmacology & pharmacy 01 natural sciences humanities 0104 chemical sciences Muraglitazar 010404 medicinal & biomolecular chemistry 03 medical and health sciences Identification (information) 0302 clinical medicine General Materials Science Biochemical engineering |
| Zdroj: | Magnetic Resonance in Chemistry. 55:283-288 |
| ISSN: | 0749-1581 |
| Popis: | Muraglitazar was being developed by Bristol-Myers Squibb for the treatment for type 2 diabetes and dislipidemia. Process optimization included the minimization of the by-products. This endeavor was greatly facilitated by a clear understanding of by-product identity. By-products were isolated by preparative chromatography and identified using NMR and MS. The identified structures of the by-products provided useful information about the undesired side reactions, which were then minimized or eliminated by altering the reaction conditions appropriately. Copyright © 2016 John Wiley & Sons, Ltd. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text